BioCentury
ARTICLE | Clinical News

Descovy emtricitabine/tenofovir alafenamide regulatory update

April 11, 2016 7:00 AM UTC

FDA approved Descovy emtricitabine/tenofovir alafenamide from Gilead to treat HIV-1 infection in patients ages >=12. Gilead launched Descovy at a wholesale acquisition cost (WAC) of $17,842 last week....